Discover key insights from ImmuCell’s Q3 2025 earnings call—leadership change, margin gains, growth focus, and outlook.
In this week's Ask the Editor Q&A, Joy Taylor answers tax questions on the 20% deduction for qualified business income or QBI ...
18hon MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
BioAtla’s Q3 2025 update details FDA-aligned Oz-V Phase III trial, peak sales forecast, strategic deal progress, and cost reductions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback